Table Ergoferon resorption 20 pc

$7.82

Table Ergoferon resorption 20 pc

Quantity:

Description

Composition
Active substance:
antibodies to human gamma interferon affinity purified – 0.006 g *
antibody affinity-purified histamine – 0.006 g *
antibodies affinity-purified CD4 – 0.006 g *
* Applied to lactose monohydrate in a mixture of three aqueous-alcoholic active substance dilutions diluted respectively at 10012, 10030, 10050 times.
Excipients:
0.267 g of lactose monohydrate, microcrystalline cellulose 0.03 g magnesium stearate 0.003 g
Description:
Ploskotsilindricheskoy tablet form with facet and Valium, from white to almost white color. On the flat side coated with Valium inscription MATERIA MEDICA, on the other flat side applied ERGOFERON inscription.
Product form:
Lozenges. 20 tablets in blisters of PVC film and aluminum foil.
1 contour cellular packaging together with instructions for medical application is placed in a pile of cardboard
Contraindications
Increased individual sensitivity to the drug.
Dosage
+ 6 mg 6 mg 6 mg +
Indications
Prevention and treatment of influenza A and B.
Prevention and treatment of acute respiratory viral infections caused by parainfluenza virus, adenovirus, respiratory syncytial virus, coronavirus.
Prevention and treatment of herpesvirus infections (labial herpes, ophthalmoherpes, genital herpes, varicella, herpes zoster, infectious mononucleosis).
Prevention and treatment of acute intestinal infections of viral etiology (caused by caliciviruses, adenovirus, coronavirus, rotavirus, enterovirus).
Prevention and treatment of meningococcal meningitis and enterovirus, hemorrhagic fever with renal syndrome, tick-borne encephalitis.
The use in the treatment of bacterial infections (pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, including caused by atypical pathogens (M.pneumoniae, C.Pneumoniae, Legionella spp)); prevention of bacterial complications of viral infections, prevention of superinfection.
Interaction with other drugs
Incompatibilities with other drugs has not yet been registered.
Overdose
Accidental overdosing possible diarrheal phenomena caused by members of the formulation excipients.
pharmachologic effect
Pharmacological group:
An antiviral agent, an antihistamine
Pharmacodynamics:
Spectrum Ergoferona pharmacological activity includes antiviral, immunomodulating, antihistamines, anti-inflammatory.
Experimentally and clinically proven efficacy of Ergoferona components for viral infectious diseases: influenza A and influenza B, acute respiratory viral infections (caused by viruses, parainfluenza, adenoviruses, respiratory syncytial viruses, coronaviruses), herpes infection (herpes labialis, ophthalmoherpes, genital herpes, herpes herpes, chickenpox, infectious mononucleosis), acute intestinal infections of viral etiology (caused by calicivirus, coronavirus, rotavirus, Ente ovirusami), enterovirus and meningococcal meningitis, hemorrhagic fever with renal syndrome, tick-borne encephalitis.
The drug used in the treatment of bacterial infections (pseudotuberculosis, whooping cough, yersiniosis, pneumonitis of different etiology, including atypical pathogens (M.pneumoniae, C.Pneumoniae, Legionella spp.), Is used to prevent bacterial complications of viral infections, prevents superinfection. Use of the drug in pre- and post-immunization period increases the effectiveness of the vaccine provides prophylaxis nonspecific SARS and influenza at the time of formation of postvaccination immunity. Ergoferon has proph nical efficacy against SARS non-influenza etiology, prevents the development of intercurrent disease following immunization.
Components in the formulation have a single mechanism of action of increasing the functional activity of CD4 receptor, receptors for interferon gamma (IFN-gamma) and histamine, respectively; which is accompanied by severe immunotropic action.
It is experimentally proved that the antibodies to interferon gamma:
increased expression of IFN-gamma, IFN alpha / beta, and conjugated with them interleukins (IL-2, IL-4, IL-10, etc.), improves the ligand-receptor interaction of IFN reduced the cytokine status; normalize the concentration and functional activity of natural antibodies to IFN-gamma, which are an important factor in the natural antiviral tolerance of an organism; interferonozavisimye stimulate biological processes: the induction of the expression of major histocompatibility complex antigens I, II and type of Fc-receptor activation of monocytes, stimulation of the functional activity of NK-cells, regulation of immunoglobulin synthesis, activating a mixed Th1 and Th2 immune response.
Antibodies to CD4, probably being allosteric modulators of the receptor, regulate the functional activity of the CD4 receptor, which leads to an increase in functional activity of CD4 lymphocytes normalization CD4 / CD8 immunoregulatory index as well as subpopulations of immunocompetent cells (CD3, CD4, CD8, CD16, CD20) .
Antibodies to the histamine modified histamine-dependent activation of the peripheral and central H1-receptors, and thus reduce the tone of the smooth muscles of the bronchi, decrease capillary permeability, which leads to a reduction in the duration and severity of runny nose, swelling of the nasal mucosa, coughing and sneezing, as well as reduces the severity of accompanying infection process allergic reactions by inhibiting histamine release from mast cells and basophils, leukotriene production, the synthesis of adhesion molecules, reduction xe otaksisa eosinophil and platelet aggregation reactions on contact with an allergen.
The combined use of components of complex preparation accompanied by increased antiviral activity of its components.
Pharmacokinetics:
Sensitivity modern physico-chemical methods of analysis (gas-liquid chromatography, high performance liquid chromatography, gas chromatography-mass spectrometry) does not allow to evaluate the content of active components Ergoferon drug in biological fluids, organs and tissues, making it impossible technically pharmacokinetics study.
Pregnancy and breast-feeding
Security applications Ergoferona during pregnancy and lactation has not been studied. If necessary, the appointment should take into account the risk / benefit ratio.
Conditions of supply of pharmacies
Without recipe
side effects
Possible reactions of individual hypersensitivity to the drug.
special instructions
The preparation includes lactose monohydrate, and therefore it is not recommended for patients with congenital galactosemia, malabsorption of glucose or galactose, or with congenital lactase deficiency.
Ergoferon does not affect the ability to drive vehicles and other potentially dangerous machinery.
Storage conditions
In the dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Inside, not during meals. The tablet should be kept in the mouth without swallowing, until complete dissolution.
Children from 6 months. In appointing the drug to young children (6 months to 3 years), it is recommended to dissolve a tablet in a small amount (1 tablespoon) of boiled water at room temperature.
In the 1 st day of treatment take 8 tablets as follows: 1 tablet every 30 minutes for the first 2 chasa (of 5 tablets for 2 hours), then during that same day accept another 1 tablet 3 times through equal time intervals. On the 2nd day and then take 1 tablet 3 times daily until full recovery.
For the prevention of viral infectious diseases – 1-2 tablets a day. The recommended duration of preventive course is determined individually and may be 1-6 months.
If necessary, medication can be combined with other antiviral and symptomatic agents.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Materia Medica

There are no reviews yet.

Add your review